Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes - a tertiary care center experience.
J Mycol Med
; 32(2): 101238, 2022 May.
Article
in English
| MEDLINE | ID: covidwho-1586952
ABSTRACT
OBJECTIVE:
To evaluate the outcome of patients with ROCM (Rhino-orbito-cerebral mucormycosis) following their medical and surgical management. MATERIALS ANDMETHODS:
It is a prognostic study based in a tertiary care center in North-Western India. Patients who developed ROCM post COVID-19 infection from 1st September 2020 to 30th June 2021 were included in this study. Surgical debridement and administration of antifungal therapy was done for the post-COVID-19 ROCM patients. Disease progression and survival was studied up to 5 months of follow-up in the second wave.RESULTS:
A total of 145 ROCM patients were included. The mean age at presentation, male female ratio was 48.2 years and 21 respectively. As per our proposed new staging system and treatment strategy, the majority of patients belonged to stage II (31.72%) and stage III (31.03%). On a follow-up period of 5 months, 26 (18%) patients have lost their life and rest of the patients are on strict follow-up.CONCLUSION:
ROCM is an extremely aggressive fungal infection which rapidly became an epidemic following the COVID-19 pandemic. The diverse and unique presentation led us to evolve a new strategy to classify and manage these patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Orbital Diseases
/
Eye Infections, Fungal
/
COVID-19
/
Mucormycosis
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
J Mycol Med
Year:
2022
Document Type:
Article
Affiliation country:
J.mycmed.2021.101238
Similar
MEDLINE
...
LILACS
LIS